MoneyWorks4Me

Ajanta Pharma informs about disclosure

02 Jun 2026 Evaluate

Ajanta Pharma has informed that it enclosed Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 02, 2026 for Ravi Agrawal, trustee Ravi Agrawal Trust.

The above information is a part of company’s filings submitted to BSE. 


Ajanta Pharma Share Price

3574.10 33.40 (0.94%)
28-Aug-2026 09:15 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1912.30
Dr. Reddys Labs. 1179.85
Cipla 1423.95
Lupin 2164.90
Zydus Lifesciences 1188.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: